Clinical experience with alemtuzumab

Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unknown function which is found on B and T lymphocytes, leading to depletion followed by repopulation of these cells. The high efficacy of Alemtuzumab in controlling relapsing remitting MS has...

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52...

Clinical Experience with Aureomycin.

FCA: forget chemoimmunotherapy with alemtuzumab?

The monoclonal antibody targeting CD52, alemtuzumab, has a more potent antileukemic activity compared with the antibody targeting CD20, rituximab. CLL cells express more CD52 than CD20.3 Finally, the combination of fludarabine with alemtuzumab (FA) was shown to be effective and safe.4,5 Hence, it seemed a logical step to combine alemtuzumab with FC chemotherapy, the most efficient backbone of c...

Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.

BACKGROUND Alemtuzumab (MabCampath) is a monoclonal antibody against CD52, indicated as third-line treatment of chronic lymphocytic leukaemia (CLL). As most important side effect opportunistic infections are mentioned. It is, however, unknown whether these complications often lead to problems in general patient care in the Netherlands. METHODS To gain insight into the use and complications of...